Overview

A Trial of Tisotumab Vedotin in Cervical Cancer

Status:
Active, not recruiting

Trial end date:
2023-04-30

Target enrollment:

Participant gender:

Summary

A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Genmab
Seagen Inc.

Collaborators:

Belgian Gynaecological Oncology Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Genmab
Gynecologic Oncology Group
Seattle Genetics, Inc.

Treatments:

Tisotumab vedotin